Teva and sanofi announce duvakitug (anti-tl1a) positive phase 2b results demonstrating best-in-class potential in ulcerative colitis and crohn's disease

Primary endpoints met in ulcerative colitis (uc) and crohn's disease (cd), the most common forms of inflammatory bowel disease (ibd) primary endpoint results in uc and cd for high dose represent the highest achieved with any tl1a monoclonal antibody sanofi and teva plan to initiate phase 3 development in ibd, pending regulatory discussions parsippany, n.j. and paris, dec. 17, 2024 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd.
TEVA Ratings Summary
TEVA Quant Ranking